|
|
|
|||||
|
|
||||
|
|||||
|
||
|
FDA批准Taxotere (docetaxel紫杉萜) 作为化疗联合用药
|
||
|
作者：佚名 化疗来源：本站原创 点击数： 更新时间：2006-10-22
|
||
Advanced Head and Neck Cancer The Food and Drug Administration (FDA) today approved Taxotere (docetaxel) Injection Concentrate for use in combination with cisplatin and fluorouracil prior to radiotherapy for the treatment of patients with inoperable, locally advanced squamous cell carcinoma of the head and neck (SCCHN). This disease represents approximately 3 percent of all new cancer cases in the United States. 紫杉萜被FDA许可联合顺铂、氟脲嘧啶用于治疗头颈癌。 "Today's approval will provide prescribers with a new treatment option that has been shown to help slow the spread of the disease and prolong patients' survival, " said Steven Galson, M.D., director of FDA's Center for Drug Evaluation and Research. |
 |
|
Copyright © 2006-2007 All Rights Reserved 版权所有：www.cncancer.com.cn
中国癌症治疗信息网 |
相关资讯